These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34211507)

  • 1. Translational Proteomics Analysis of Anthracycline-Induced Cardiotoxicity From Cardiac Microtissues to Human Heart Biopsies.
    Nguyen N; Souza T; Verheijen MCT; Gmuender H; Selevsek N; Schlapbach R; Kleinjans J; Jennen D
    Front Genet; 2021; 12():695625. PubMed ID: 34211507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longitudinal evaluation of oxidative stress - mitochondrial dysfunction - ferroptosis genes in anthracycline-induced cardiotoxicity.
    Qianqian R; Peng Z; Licai Z; Ruizhi Z; Tianhe Y; Xiangwen X; Chuansheng Z; Fan Y
    BMC Cardiovasc Disord; 2024 Jul; 24(1):350. PubMed ID: 38987722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptome analysis of long noncoding RNAs reveals their potential roles in anthracycline-induced cardiotoxicity.
    Nguyen N; Souza T; Kleinjans J; Jennen D
    Noncoding RNA Res; 2022 Jun; 7(2):106-113. PubMed ID: 35415316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
    Robert J
    Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anthracyclines and the heart].
    Mazzarello GP; Morra L
    Recenti Prog Med; 1998 Sep; 89(9):459-64. PubMed ID: 9796378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
    Platel D; Pouna P; Bonoron-Adèle S; Robert J
    Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
    Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
    Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2010 Mar; (3):CD005006. PubMed ID: 20238335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.
    Swift L; McHowat J; Sarvazyan N
    Cancer Res; 2003 Sep; 63(18):5992-8. PubMed ID: 14522926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
    Ghigo A; Li M; Hirsch E
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncoupling DNA damage from chromatin damage to detoxify doxorubicin.
    Qiao X; van der Zanden SY; Wander DPA; Borràs DM; Song JY; Li X; van Duikeren S; van Gils N; Rutten A; van Herwaarden T; van Tellingen O; Giacomelli E; Bellin M; Orlova V; Tertoolen LGJ; Gerhardt S; Akkermans JJ; Bakker JM; Zuur CL; Pang B; Smits AM; Mummery CL; Smit L; Arens R; Li J; Overkleeft HS; Neefjes J
    Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15182-15192. PubMed ID: 32554494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions.
    Osataphan N; Phrommintikul A; Chattipakorn SC; Chattipakorn N
    J Cell Mol Med; 2020 Jun; 24(12):6534-6557. PubMed ID: 32336039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network integration and modelling of dynamic drug responses at multi-omics levels.
    Selevsek N; Caiment F; Nudischer R; Gmuender H; Agarkova I; Atkinson FL; Bachmann I; Baier V; Barel G; Bauer C; Boerno S; Bosc N; Clayton O; Cordes H; Deeb S; Gotta S; Guye P; Hersey A; Hunter FMI; Kunz L; Lewalle A; Lienhard M; Merken J; Minguet J; Oliveira B; Pluess C; Sarkans U; Schrooders Y; Schuchhardt J; Smit I; Thiel C; Timmermann B; Verheijen M; Wittenberger T; Wolski W; Zerck A; Heymans S; Kuepfer L; Roth A; Schlapbach R; Niederer S; Herwig R; Kleinjans J
    Commun Biol; 2020 Oct; 3(1):573. PubMed ID: 33060801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human heart cytosolic reductases and anthracycline cardiotoxicity.
    Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
    IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity.
    Tokarska-Schlattner M; Wallimann T; Schlattner U
    Mol Pharmacol; 2002 Mar; 61(3):516-23. PubMed ID: 11854431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.
    Salvatorelli E; Menna P; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
    J Pharmacol Exp Ther; 2012 May; 341(2):464-73. PubMed ID: 22338033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites.
    Salvatorelli E; Menna P; Chello M; Covino E; Minotti G
    J Pharmacol Exp Ther; 2018 Feb; 364(2):323-331. PubMed ID: 29222131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.